Pristine B40 fullerene as a potential gemcitabine drug carrier for anti-lung cancer properties: a DFT and QTAIM study

被引:1
|
作者
Sukumar, Abisha Nancy [1 ]
Duraisamy, Parimala Devi [1 ]
Paul, Prince Makarios [1 ]
Gopalan, Praveena [2 ]
Angamuthu, Abiram [1 ]
机构
[1] Karunya Inst Technol & Sci, Dept Phys Sci, Coimbatore, Tamil Nadu, India
[2] PSGR Krishnammal Coll Women, Dept Phys, Coimbatore, Tamil Nadu, India
来源
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS | 2024年
关键词
DFT; nanostructures; drug interaction; lung cancer; QTAIM; ANTICANCER DRUG; THEORETICAL APPROACH; ADSORPTION; AL; SI; DEOXYCYTIDINE; DECOMPOSITION; HARDNESS; SPECTRA; SURFACE;
D O I
10.1080/07391102.2024.2431665
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Novel biomedical applications of various nanomaterials are being extensively researched as drug delivery systems. These nanomaterials deliver various anticancer treatments into the specific tumor cell sites, which reduces their terrible side effects. In this study, we have used DFT/B3LYP/6-311++G(d,p) level of theory to examine the efficacy of the pristine B40 fullerene (Boron) as a drug delivery vehicle for gemcitabine an anti-lung cancer medication at various position. From our investigation the most stable adsorption orientation was observed between double bonded oxygen atom of the drug and six membered ring boron atoms of B40 fullerene both in gas and solvent phases. The frontier molecular orbitals and QTAIM studies further support the interaction of gemcitabine medication with the B40 fullerene. NBO and MEP methods show substantial charge transfer from gemcitabine drug molecules to the fullerene. Overall, the results suggest that the B40 fullerene effectively adsorbs the drug and hence can be used as a tool for drug delivery system.
引用
收藏
页数:14
相关论文
共 33 条
  • [31] Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer
    Gerber, David E.
    Infante, Jeffrey R.
    Gordon, Michael S.
    Goldberg, Sarah B.
    Martin, Miguel
    Felip, Enriqueta
    Martinez Garcia, Maria
    Schiller, Joan H.
    Spigel, David R.
    Cordova, Julie
    Westcott, Valerie
    Wang, Yulei
    Shames, David S.
    Choi, YounJeong
    Kahn, Robert
    Dere, Randall C.
    Samineni, Divya
    Xu, Jian
    Lin, Kedan
    Wood, Katie
    Royer-Joo, Stephanie
    Lemahieu, Vanessa
    Schuth, Eva
    Vaze, Anjali
    Maslyar, Daniel
    Humke, Eric W.
    Burris, Howard A., III
    CLINICAL CANCER RESEARCH, 2020, 26 (02) : 364 - 372
  • [32] SAFETY, PHARMACOKINETICS, AND ACTIVITY OF THE ANTI-NAPI2B ANTIBODY-DRUG CONJUGATE DNIB0600A: A PHASE I STUDY IN PATIENTS WITH NON-SMALL CELL LUNG CANCER AND PLATINUM-RESISTANT OVARIAN CANCER
    Gerber, David
    Infante, Jeffrey
    Gordon, Michael
    Schiller, Joan
    Spigel, David
    Wang, Yulei
    Shames, David S.
    Choi, Younjeong
    Kahn, Robb
    Xu, Jian
    Lin, Kedan
    Wood, Katie
    Maslyar, Daniel
    Burris, Howard
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1190 - S1191
  • [33] A phase I study of the safety and pharmacokinetics of DNIB0600A, an anti-NaPi2b antibody-drug-conjugate (ADC), in patients (pts) with non- small cell lung cancer (NSCLC) and platinum-resistant ovarian cancer (OC).
    Gordon, Michael S.
    Gerber, David E.
    Infante, Jeffrey R.
    Xu, Jian
    Shames, David S.
    Choi, Younjeong
    Kahn, Robert S.
    Lin, Kedan
    Wood, Katie
    Maslyar, Daniel J.
    Burris, Howard A.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)